Wealth Enhancement Advisory Services
HRTX icon

Wealth Enhancement Advisory Services’s Heron Therapeutics HRTX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4K Buy
32,397
+15,793
+95% +$12.7K ﹤0.01% 4081
2026
Q1 		$13.3K Buy
+16,604
New +$19.2K ﹤0.01% 3537
2025
Q4 		– Sell
-25,577
Closed -$33.8K – 3715
2025
Q3 		$33.8K Sell
25,577
-11,551
-31% -$18.3K ﹤0.01% 3463
2025
Q2 		$81.7K Buy
37,128
+1,512
+4% +$3.09K ﹤0.01% 3169
2025
Q1 		$78.4K Buy
35,616
+482
+1% +$935 ﹤0.01% 2806
2024
Q4 		$53.8K Sell
35,134
-10,139
-22% -$16.4K ﹤0.01% 2860
2024
Q3 		$90.1K Buy
45,273
+7,927
+21% +$18.9K ﹤0.01% 2575
2024
Q2 		$131K Buy
37,346
+1,366
+4% +$4.2K ﹤0.01% 2368
2024
Q1 		$99.7K Buy
35,980
+9
+0% +$23 ﹤0.01% 2295
2023
Q4 		$61.2K Sell
35,971
-1,640
-4% -$1.81K ﹤0.01% 2205
2023
Q3 		$38.7K Buy
+37,611
New +$53.5K ﹤0.01% 2171

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Wealth Enhancement Advisory Services's HRTX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Heron Therapeutics (HRTX) stake by 95% in Q2 2026, buying an estimated $12.7K and bringing the position to 32,397 shares worth $13.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4081.

Wealth Enhancement Advisory Services first reported a position in HRTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $131K in Q2 2024. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Wealth Enhancement Advisory Services held 32,397 shares of Heron Therapeutics worth $13.4K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 15,793 Heron Therapeutics shares in Q2 2026, an estimated $12.7K.
  • Heron Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #4081 holding.
  • Wealth Enhancement Advisory Services first reported a position in Heron Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Wealth Enhancement Advisory Services's Heron Therapeutics position peaked at $131K in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.